section name header

Pronunciation ⬇

pen-i-SILL-in vee

Classifications ⬆ ⬇

Therapeutic Classification: anti-infectives

Pharmacologic Classification: penicillins

Indications ⬆ ⬇

REMS

Unlabeled Use:
  • Treatment of Lyme disease.
  • Prevention of recurrent

    Streptococcal pneumoniae

    septicemia in children with sickle-cell disease.

Action ⬆ ⬇

  • Bind to bacterial cell wall, resulting in cell death.
Therapeutic effects:
  • Bactericidal action against susceptible bacteria.

Spectrum:

Pharmacokinetics ⬆ ⬇

Absorption: Variably absorbed from the GI tract. Resists acid degradation in the GI tract.

Distribution: Widely distributed, although CNS penetration is poor in the presence of normal (non-inflamed) meninges. Crosses the placenta and enters breast milk.

Protein Binding: 60%.

Metabolism/Excretion: Minimally metabolized by the liver, excreted mainly unchanged by the kidneys.

Half-Life: 30–60 min.

Time/Action Profile ⬆ ⬇

(blood levels)

ROUTEONSETPEAKDURATION
POrapid0.5–1 hr4–6 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: rash, urticaria

GI: diarrhea, epigastric distress, nausea, vomiting, Clostridioides difficile-associated diarrhea (CDAD)

GU: interstitial nephritis

Hemat: eosinophilia, leukopenia

Neuro: SEIZURES

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND SERUM SICKNESS) , superinfection

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Pen VK

Code ⬆

NDC Code